Cizzle Biotechnology Holdings PLC develops diagnostic tests for early cancer detection, focusing on lung cancer. The company has created a non-invasive blood test based on the CIZ1B biomarker, which is associated with early-stage lung cancer. Cizzle generates revenue through commercial royalty-bearing arrangements to license its technology and collaborates with cancer care centers. It operates primarily in the UK and aims to improve early cancer diagnosis through its proprietary testing methods.